Sign In
Buy SBRA
Sabra Healthcare REIT Earnings Calls
| Release date | Apr 29, 2026 |
| EPS estimate | $0.167 |
| EPS actual | $0.390 |
| EPS Surprise | 133.95% |
| Revenue estimate | 209.198M |
| Revenue actual | 221.753M |
| Revenue Surprise | 6.00% |
| Release date | Feb 12, 2026 |
| EPS estimate | $0.170 |
| EPS actual | $0.380 |
| EPS Surprise | 123.53% |
| Revenue estimate | 197.974M |
| Revenue actual | 211.902M |
| Revenue Surprise | 7.04% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.380 |
| EPS actual | $0.380 |
| Revenue estimate | 201.965M |
| Revenue actual | 190.037M |
| Revenue Surprise | -5.91% |
| Release date | Aug 04, 2025 |
| EPS estimate | $0.370 |
| EPS actual | $0.380 |
| EPS Surprise | 2.70% |
| Revenue estimate | 187.471M |
| Revenue actual | 189.15M |
| Revenue Surprise | 0.90% |
Last 4 Quarters for Sabra Healthcare REIT
Below you can see how SBRA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 04, 2025 |
| Price on release | $18.41 |
| EPS estimate | $0.370 |
| EPS actual | $0.380 |
| EPS surprise | 2.70% |
| Date | Price |
|---|---|
| Jul 29, 2025 | $18.16 |
| Jul 30, 2025 | $17.96 |
| Jul 31, 2025 | $18.03 |
| Aug 01, 2025 | $18.29 |
| Aug 04, 2025 | $18.41 |
| Aug 05, 2025 | $18.18 |
| Aug 06, 2025 | $18.41 |
| Aug 07, 2025 | $18.68 |
| Aug 08, 2025 | $18.72 |
| 4 days before | 1.38% |
| 4 days after | 1.68% |
| On release day | -1.25% |
| Change in period | 3.08% |
| Release date | Nov 05, 2025 |
| Price on release | $18.20 |
| EPS estimate | $0.380 |
| EPS actual | $0.380 |
| Date | Price |
|---|---|
| Oct 30, 2025 | $17.47 |
| Oct 31, 2025 | $17.82 |
| Nov 03, 2025 | $17.89 |
| Nov 04, 2025 | $17.98 |
| Nov 05, 2025 | $18.20 |
| Nov 06, 2025 | $18.85 |
| Nov 07, 2025 | $18.88 |
| Nov 10, 2025 | $19.08 |
| Nov 11, 2025 | $19.16 |
| 4 days before | 4.18% |
| 4 days after | 5.27% |
| On release day | 3.57% |
| Change in period | 9.67% |
| Release date | Feb 12, 2026 |
| Price on release | $20.25 |
| EPS estimate | $0.170 |
| EPS actual | $0.380 |
| EPS surprise | 123.53% |
| Date | Price |
|---|---|
| Feb 06, 2026 | $19.03 |
| Feb 09, 2026 | $19.09 |
| Feb 10, 2026 | $19.15 |
| Feb 11, 2026 | $19.60 |
| Feb 12, 2026 | $20.25 |
| Feb 13, 2026 | $20.17 |
| Feb 17, 2026 | $20.59 |
| Feb 18, 2026 | $20.03 |
| Feb 19, 2026 | $20.02 |
| 4 days before | 6.41% |
| 4 days after | -1.14% |
| On release day | -0.395% |
| Change in period | 5.20% |
| Release date | Apr 29, 2026 |
| Price on release | $20.35 |
| EPS estimate | $0.167 |
| EPS actual | $0.390 |
| EPS surprise | 133.95% |
| Date | Price |
|---|---|
| Apr 23, 2026 | $19.91 |
| Apr 24, 2026 | $20.09 |
| Apr 27, 2026 | $20.29 |
| Apr 28, 2026 | $20.53 |
| Apr 29, 2026 | $20.35 |
| Apr 30, 2026 | $20.66 |
| May 01, 2026 | $20.36 |
| May 04, 2026 | $20.46 |
| May 05, 2026 | $20.38 |
| 4 days before | 2.21% |
| 4 days after | 0.147% |
| On release day | 1.52% |
| Change in period | 2.36% |
Sabra Healthcare REIT Earnings Call Transcript Summary of Q1 2026
Sabra reported a strong Q1 2026 driven by robust SHOP (senior housing operating) deal flow and continued improvement across portfolios. Year-to-date closed/awarded investments total about $400 million, with an additional $690 million of SHOP opportunities being actively pursued; management expects to materially exceed 2025 investment levels. SHOP same-store metrics were strong: revenue +7.9% YoY, occupancy +280 bps to 88.4% (Canada 93.4%), RevPAR +4.6% YoY, and same-store cash NOI +14.4% YoY. For the first time, private-pay revenue represents ~50% of the portfolio. Normalized FFO and AFFO per share were $0.38 and $0.39, up ~9% and ~5% YoY, respectively. Leverage remains within target: net debt / adjusted EBITDA 5.04x, weighted-average permanent debt cost 3.92%, ~4-year weighted-term, and ample liquidity ~ $1.2 billion (cash $117M, revolver availability $645M, $451M outstanding forward ATM proceeds). Management reaffirmed 2026 guidance but will revisit in Q2 as visibility improves. Subsequent actions: sold three CommuniCare-leased SNFs for gross proceeds $79.4M (6.8% lease yield); board declared $0.30 quarterly dividend (covered at ~77% of Q1 normalized AFFO). Management emphasized AI and automation initiatives to scale the SHOP platform and accelerate decision-making and operator support.
